

# 1 Preparation of Cationic Nanogels for Nucleic Acid Delivery


2 Saadyah E. Averick,<sup>†</sup> Eduardo Paredes,<sup>‡</sup> Arun R. Shrivats,<sup>§</sup> Ainara Irastorza,<sup>§</sup> Abiraman Srinivasan,<sup>†</sup>  
 3 Daniel J. Siegwart,<sup>†</sup> Andrew J. Magenau,<sup>†</sup> Hong Y. Cho,<sup>†</sup> Eric Hsu,<sup>§</sup> Amram Averick,<sup>†</sup> Jinku Kim,<sup>§</sup>  
 4 Shiguang Liu,<sup>§</sup> Jeffrey O. Hollinger,<sup>§</sup> Subha Das,<sup>‡</sup> and Krzysztof Matyjaszewski\*<sup>†</sup>

5 <sup>†</sup>Department of Chemistry and <sup>‡</sup>Center for Nucleic Acids Science and Technology, Carnegie Mellon University, 4400 Fifth Avenue,  
 6 Pittsburgh, Pennsylvania 15213, United States

7 <sup>§</sup>Bone Tissue Engineering Center, Departments of Biomedical Engineering and Biological Sciences, Carnegie Mellon University,  
 8 Pittsburgh, Pennsylvania 15219, United States

## 9 Supporting Information

10 **ABSTRACT:** Cationic nanogels with site-selected function-  
 11 ality were designed for the delivery of nucleic acid payloads  
 12 targeting numerous therapeutic applications. Functional  
 13 cationic nanogels containing quaternized 2-(dimethylamino)-  
 14 ethyl methacrylate and a cross-linker with reducible disulfide  
 15 moieties (qNG) were prepared by electron transfer  
 16 (AGET) atom transfer radical polymerization (ATRP) in an  
 17 inverse miniemulsion. Polyplex formation between the qNG  
 18 and nucleic acid exemplified by plasmid DNA (pDNA) and  
 19 short interfering RNA (siRNA duplexes) were evaluated. The delivery of polyplexes was optimized for the delivery of pDNA and  
 20 siRNA to the *Drosophila* Schneider 2 (S2) cell-line. The qNG/nucleic acid (i.e., siRNA and pDNA) polyplexes were found to be  
 21 highly effective in their capabilities to deliver their respective payloads.



22 **S**hort interfering RNA (siRNA) and plasmid DNA (pDNA)  
 23 have emerged as important agents in both basic research  
 24 and therapeutic strategies.<sup>1–4</sup> They affect the biosynthesis of  
 25 their targeted proteins either through the introduction of  
 26 specific units, resulting in synthesis of new proteins, in the case  
 27 of pDNA, or targeting of messenger RNAs (mRNAs) for RNA  
 28 interference (RNAi), as in the case of siRNA.<sup>5,6</sup> The selective  
 29 delivery of siRNA and pDNA has been a challenge due to their  
 30 degradation in the presence of nuclease and their anionic  
 31 charge that hinders their cell permeability.<sup>7,8</sup> Solutions include  
 32 cationic carrier systems, such as cationic lipids or polymers,  
 33 which generate complexes via electrostatic interactions to form  
 34 of lipoplexes or polyplexes, respectively, and thus enhance the  
 35 transfection of nucleic acids into cells.<sup>9–24</sup> Nevertheless, the  
 36 design of efficient polyplex-based siRNA and pDNA delivery  
 37 systems for transfection is itself a challenge that limits realizing  
 38 the full potential of siRNA and pDNA for therapeutic  
 39 applications.<sup>4,8,25–28</sup>

40 Previously, the preparation of biodegradable cross-linked  
 41 nanogels (NGs),<sup>11</sup> comprising an oligo(ethylene oxide)  
 42 methacrylate (OEOMA) backbone was demonstrated using  
 43 by electron transfer atom transfer radical polymerization  
 44 (AGET ATRP) in inverse miniemulsion.<sup>29–31</sup> This method  
 45 was successfully used to prepare protein–polymer hybrid  
 46 NGs<sup>32,33</sup> and NGs for delivery of small molecules<sup>34</sup> and  
 47 carbohydrates.<sup>35</sup> However, in order to use these materials for  
 48 effective nucleic acid delivery, it is necessary to have site-specific  
 49 incorporation of cationic monomers, into the predominant  
 50 OEOMA NGs for polyplex formation, but currently this has



not been accomplished. ATRP<sup>36–39</sup> is a versatile polymer-  
 51 ization method that can be applied for the synthesis of diverse  
 52 and complex polymeric architectures,<sup>40–44</sup> including cationic  
 53 and quaternized nanogels (qNGs). In this communication, we  
 54 report the synthesis of a biodegradable qNG via the  
 55 copolymerization of OEOMA and a cationic monomer,  
 56 quaternized dimethylaminoethyl methacrylate,<sup>45,45</sup> by AGET  
 57 ATRP in inverse miniemulsion. A disulfide-based cross-  
 58 linker<sup>9,30,46–48</sup> was utilized to take advantage of the different  
 59 concentrations of reducing agent contained in the extracellular  
 60 (~1  $\mu$ M) versus intracellular (~10 mM) matrix<sup>49,50</sup> and  
 61 facilitate the biodegradation of the NG after transfection of the  
 62 nucleic acid cargo. The qNGs were studied for the complex-  
 63 ation and delivery of a pDNA that codes for a firefly luciferase  
 64 protein and siRNA that targets a renilla luciferase mRNA for a  
 65 dual luciferase reporter assay. The *Drosophila* Schneider 2 (S2)  
 66 cell line was used as the model because of its importance and  
 67 prevalence in basic biological research and challenges in  
 68 successfully delivering both siRNA and pDNA to these cells.<sup>51</sup>  
 69

The biodegradable qNG were prepared in a water-in-oil  
 70 inverse miniemulsion utilizing AGET ATRP (Scheme 1).  
 71 Cu<sup>(II)</sup>Br<sub>2</sub>/tris(2-pyridylmethyl)amine (TPMA) was used as the  
 72 ATRP catalytic species, poly(ethylene glycol) methyl ether 2-  
 73 bromoisobutyrate (PEGMI<sub>2000</sub>,  $M_n$  = 2000) as a macroinitiator,  
 74 oligo(ethylene oxide)methacrylate (OEOMA<sub>300</sub>,  $M_n$  = 300),  
 75


Received: July 25, 2012

Revised: September 5, 2012

## Scheme 1. Synthesis of Cationic NGs for Nucleotide Delivery of siRNA and pDNA Using AGET ATRP



**Figure 1.** Normalized volume distribution of cationic NGs prepared by AGET ATRP in inverse miniemulsion measured using DLS. (A) Volume distribution of purified qNG prepared from PEOMI<sub>2000</sub>:OEOMA<sub>300</sub>:Q-DMAEMA:DMA:Cu(II)Br<sub>2</sub>:Ascorbic Acid: 1/290/20/4/0.5/0.6/0.3, 55 mg PEGOH<sub>2000</sub>, in 5% Span80 in cyclohexane for 24 h at 30 °C. Size = 275 nm, PDI = 0.164,  $\zeta$  potential = 43.7 mV  $\pm$ 4.1. (B) Volume distribution of qNG after incubation with 10 mM glutathione for 4 days.




**Figure 2.** Agarose gel electrophoresis analysis of polyplex formation and disassociation of qNG and pDNA (LacZ-plasmid). Electrophoresis was conducted for 30 min, at 100 V, and the gels were stained with EtBr and imaged with UV-transillumination. (A) Polyplex formation, 500 ng of plasmid was incubated with varying amounts of qNG (R1-R500) for 1 h at 25 °C and then loaded onto a 1% agarose gel electrophoresis. (B) Preformed polyplexes of qNG:pDNA (R1-R200) were incubated with 0.015  $\mu$ g/ $\mu$ L Heparin sulfate for 30 min and then examined by gel electrophoresis using a 0.5% agarose gel.

76 and quaternized dimethylaminoethyl methacrylate (Q-DMAE-  
77 MA, DMAEMA was quaternized with ethyl bromide) as  
78 comonomers, dithiopropionyl poly(ethylene glycol) dimetha-  
79 crylate (DMA) ( $M_n$  =1260) as a cross-linking agent, and  
80 PEG<sub>2000</sub>OH as a stabilizer. They were dissolved in 1.40 mL of  
81 ultrapure water and added to a 25 mL solution of 0.05% (w/w)  
82 of Span-80 in cyclohexane. The reaction mixture was emulsified  
83 using ultrasonication to form stable water-in-oil droplets. The  
84 mixture was degassed with nitrogen and a degassed solution of  
85 ascorbic acid was injected into the emulsion to convert  
86 Cu(II)Br<sub>2</sub> to Cu(I)Br and initiate the AGET ATRP. The  
87 polymerization was carried out for 24 h at 30 °C. The qNGs  
88 were purified by precipitation into THF, then washed several

times with ultrapure water followed by dialysis (25 k MWCO  
89 membrane) against water to remove all unreacted reagents. 90

The qNGs were characterized by dynamic light scattering  
91 (DLS) and zeta potential, revealing a particle size of ca. 275 nm  
92 in diameter with a CV of 0.164 and 43.7 mV  $\pm$ 4.1, respectively  
93 (Figure 1A). To determine the biodegradability of these qNGs  
94 under reducing conditions, a 1 mg/mL solution of qNG in 10  
95 mM glutathione<sup>9</sup> was prepared, and its particle size was  
96 monitored using DLS. The resulting degraded particles had a  
97 volume distribution of ca. 4 nm in diameter, indicating a  
98 successful REDOX mediated degradation of the qNG  
99 (Figure 1B). 100




**Figure 3.** Agarose gel electrophoresis complexation assay measured at varying qNG:siRNA weight ratios. (A) Polyplexes were prepared by incubating 500 ng of siRNA with varying amounts of qNG for 1 h at 4 °C, then loaded onto a 2% agarose gel in Tris/Borate/EDTA buffer. After electrophoresis (30 min, 100 V) the gel was stained with EtBr and imaged with UV-transillumination. (B) Preformed polyplexes of qNG:siRNA (R1–R50) were incubated with 0.05  $\mu\text{g}/\mu\text{L}$  Heparin sulfate for 30 min and then examined by gel electrophoresis using a 3% agarose gel.

101 The ability of the qNG to complex both pDNA and siRNA  
 102 was investigated using agarose gel shift assay. This assay was  
 103 used to determine the weight ratio, R (i.e., NG:siRNA or  
 104 NG:pDNA), at which qNG totally complexed pDNA and  
 105 siRNA, respectively. Five hundred nanograms of pDNA was  
 106 hybridized with qNG for 1 h at 25 °C (in nuclease-free  
 107 ultrapure water pH = 7) and then loaded onto a 1% agarose gel.  
 108 Following electrophoresis, the gels were stained with ethidium  
 109 bromide (EtBr) and imaged. For pDNA, a ratio of R5 (i.e.,  
 110  $\text{weight}_{\text{qNG}}:\text{weight}_{\text{pDNA}} = 5:1$ ) showed a lack of band migration  
 111 of the qNG:pDNA polyplex. This indicated a near total  
 112 complexation of the DNA with the qNG (Figure 2A). A  
 113 polyplex disassociation study was conducted, by adding heparin  
 114 sulfate to the precomplexed qNG:pDNA polyplexes, to  
 115 determine the reversibility of the complexation between qNG  
 116 and pDNA.<sup>52</sup> At ratios less than R50, the polyplexes could be  
 117 disassociated using heparin sulfate (0.015  $\mu\text{g}/\mu\text{L}$ ) (Figure 2B).  
 118 This result suggests that, although pDNA could be complexed,  
 119 it could be released, when a small excess of qNG was used to  
 120 complex the pDNA. Preliminary characterization of  
 121 qNG:pDNA polyplexes using DLS and  $\zeta$  potential analysis  
 122 was conducted (Figure SI-1, Supporting Information). No  
 123 aggregates were observed in the volume % distribution of  
 124 qNG:pDNA polyplexes at R values (w/w) of R2–R0.5. The  $\zeta$   
 125 potential of qNG:pDNA polyplexes for these R values are  
 126 negative, indicating successful pDNA complexation. qNG:siR-  
 127 NA polyplexes were studied by incubating 500 ng of siRNA  
 128 with varying ratios of qNG for 1 h at 4 °C (in nuclease-free  
 129 ultrapure water pH = 7). Band migration of these polyplexes  
 130 was studied by electrophoresis on a 2% agarose gel followed by  
 131 EtBr staining and imaging. At a weight ratio of 15:1  
 132 qNG:siRNA (i.e., R15), no band migration was observed  
 133 (Figure 3A), indicating total complexation of siRNA. Heparin  
 134 sulfate-mediated qNG:siRNA polyplex disassociation was  
 135 studied by incubating of preformed polyplexes at ratios of  
 136 R2.5–R50 with heparin sulfate and analyzing with a 3% agarose  
 137 gel (Figure 3B). The decomplexation studies of qNG:siRNA  
 138 polyplexes indicate that, at a ratios less than R25, the siRNA  
 139 can be released from the qNG via polyelectrolyte displacement.  
 140 Once the qNG's ability to complex nucleotides was determined,  
 141 the delivery of the polyplexes of qNG and siRNA and pDNA to  
 142 S2 cells was studied.

143 Next, we tested the ability of the qNG to act as gene delivery  
 144 (pDNA) agents using S2 cells. A firefly luciferase reporter  
 145 plasmid (FLuc) polyplex was prepared at different weight ratios  
 146 of qNG:pDNA and transfected into S2 cells. Different polyplex  
 147 formation ratios were used to identify the conditions leading to


maximal firefly luciferase signal after 24 h. Of the polyplexes 148  
 tested, the R30 polyplex resulted in a maximum emission of the 149  
 FLuc reporter gene signal (Figure 4). A paired Students t-Test 150 f4



**Figure 4.** pDNA delivery using a firefly luciferase reporter assay: Graph of FLuc activity in S2 cells after 24 h of treatment with ( $N = 3$ ): pDNA with no transfection reagent, i.e., pDNA with no FuGENE or qNG (negative control, red bar), 20 ng FLuc plasmid with FuGene-HD (positive control) or a weight ratio of qNG:pDNA(20 ng) polyplexes at (R1500, R300, R30, R15, R3, R0.3 and R0.03) (experimental group).

was used to compare the efficacies of the qNG:pDNA 151  
 polyplexes and FuGENE-HD. The polyplexes prepared at R 152  
 values of 300, 30, and 15 did not differ significantly from pDNA 153  
 transfected with Fugene-HD ( $p > .05$ ). 154

The qNGs ability to deliver siRNA was tested using a dual 155  
 luciferase reporter assay (Dual-Glo luciferase reporter assay, 156  
 Promega)<sup>53</sup> with S2 cells transfected with both firefly luciferase 157  
 and Renilla luciferase (RLuc). Three hours after reporter 158  
 plasmids were transfected, polyplexes of qNG and siRNA 159  
 against RLuc were formed at R100, R20, R2, R1, R0.2 and 160  
 R0.02, which were used to determine the optimal siRNA 161  
 transfection R values. After 24 h, the post siRNA transfection 162  
 RLuc and FLuc signals were measured, and the RLuc 163  
 knockdown was quantified and normalized to the FLuc signal 164  
 and a control well ( $N = 3$ ). When no transfection reagent (i.e., 165  
 no Fugene-HD or qNG) was used, the siRNA was inactive 166  
 (Red bar), suggesting the initial transfection agent used to 167  
 deliver the plasmid had been washed away. Maximum RLuc 168  
 reporter signal knockdown was observed at a ratio of R0.2 169  
 (Figure 5). A paired Students *t*-Test was used to compare 170 f5



**Figure 5.** siRNA delivery using a dual-Luciferase reporter assay. Normalized to FLuc, RLuc activity in S2 cells after 24 h treatment with siRNA with no transfection reagent, i.e., siRNA with no FuGENE or qNG (negative control), 9 pmol of duplex siRNA with FuGene-HD (positive control), or a weight ratio of qNG:siRNA at R100, R20, R2, R0.2 and R0.02 (experimental group).

171 qNg:siRNA polyplexes efficiency compared to FuGENE-HD.  
 172 The efficacy of the polyplexes prepared at R values of 2, 1, and  
 173 0.2 were found not to differ significantly from the efficacy of  
 174 siRNA transfected with Fugene-HD ( $p > .05$ ). This result  
 175 underscores the utility of the qNGs for siRNA delivery.

## 176 ■ CONCLUSIONS

177 We have demonstrated that well-defined qNGs (275 nm, PDI  
 178 0.164) can be prepared using AGET ATRP in inverse  
 179 miniemulsion. The disulfide cross-linker conferred biodegrad-  
 180 ability to the qNG, causing it to undergo a REDOX-mediated  
 181 degradation with glutathione, a model biological reducing  
 182 agent. Moreover, the qNGs complexed pDNA and siRNA at  
 183 relatively low weight ratios of qNG to DNA (5:1) and qNG to  
 184 siRNA (15:1), as determined by agarose gel electrophoresis.  
 185 Further, the NGs provided a robust delivery system for pDNA  
 186 (~5 kb) as well as siRNA. On the basis of the electrophoresis  
 187 disassociation experiments, we hypothesize that a balance  
 188 between tight binding of nucleic acids to the qNG and ability to  
 189 dissociate must be achieved for effective release and delivery of  
 190 complexed material. In order to characterize the ability of  
 191 different ratios of qNG to transfect siRNA, a dual-luciferase  
 192 reporter assay was utilized to rapidly and accurately screen  
 193 knockdown efficiency. A maximum reporter knockdown was  
 194 obtained at R0.2, with efficacy suggesting more effective  
 195 transfection than siRNA-Fugene-HD. For pDNA transfection,  
 196 the maximum firefly luciferase reporter signal was observed at  
 197 R30. These results confirm that qNGs are a promising platform  
 198 for pDNA and siRNA delivery and future studies will include  
 199 clinically relevant mammalian cells treated with the polyplexes.

## 200 ■ ASSOCIATED CONTENT

### 201 ● Supporting Information

202 See Supporting Information (SI) for detailed NG synthesis,  
 203 siRNA and pDNA transfection experiments, materials,  
 204 methods, and additional studies of qNG:pDNA polyplex size  
 205 and zeta potential characterizations. The qNG's effect on  
 206 MC3T3 cell viability can also be found in the SI. This

information is available free of charge via the Internet at <http://pubs.acs.org/>.

## 209 ■ AUTHOR INFORMATION

### 210 Corresponding Author

\*Fax: 412-268-6897; tel: 412-268-3209; e-mail: km3b@andrew.cmu.edu.

### 213 Author Contributions

The manuscript was written through the contributions of all authors. All authors have given approval to the final version of the manuscript.

### 217 Notes

The authors declare no competing financial interest.

## 219 ■ ACKNOWLEDGMENTS

We thank Wenwen Li for fruitful discussions. Financial support for this research was provided by DMRDP (DoD) Grant W81XWH1120073 and the NSF (DMR 09-69301)

## 223 ■ REFERENCES

- (1) Dykxhoorn, D. M.; Lieberman, J. The silent revolution: RNA interference as basic biology, research tool, and therapeutic. *Annu. Rev. Med.* **2005**, *56*, 401–23.
- (2) Hamilton, A. J.; Baulcombe, D. C. A species of small antisense RNA in posttranscriptional gene silencing in plants. *Science* **1999**, *286*, 950–2.
- (3) Fire, A.; Xu, S.; Montgomery, M. K.; Kostas, S. A.; Driver, S. E.; Mello, C. C. Potent and specific genetic interference by double-stranded RNA in *Caenorhabditis elegans*. *Nature* **1998**, *391*, 806–11.
- (4) Verma, I. M.; Somia, N. Gene therapy - Promises, problems and prospects. *Nature* **1997**, *389*, 239–42.
- (5) Lu, Q. L.; Bou-Gharios, G.; Partridge, T. A. Non-viral gene delivery in skeletal muscle: A protein factory. *Gene Ther.* **2003**, *10*, 131–42.
- (6) Li, Z.; Rana, T. M. Molecular mechanisms of RNA-triggered gene silencing machineries. *Acc. Chem. Res.* **2012**, *45*, 1122–31.
- (7) Aagaard, L.; Rossi, J. J. RNAi therapeutics: Principles, prospects and challenges. *Adv. Drug Delivery Rev.* **2007**, *59*, 75–86.
- (8) Li, S.; Huang, L. Nonviral gene therapy: Promises and challenges. *Gene Ther.* **2000**, *7*, 31–34.
- (9) Cho, H. Y.; Srinivasan, A.; Hong, J.; Hsu, E.; Liu, S.; Shrivats, A.; Kwak, D.; Bohaty, A. K.; Paik, H.-j.; Hollinger, J. O.; Matyjaszewski, K. Synthesis of biocompatible PEG-based star polymers with cationic and degradable core for siRNA delivery. *Biomacromolecules* **2011**, *12*, 3478–86.
- (10) Cho, H. Y.; Gao, H.; Srinivasan, A.; Hong, J.; Bencherif, S. A.; Siegwart, D. J.; Paik, H.-j.; Hollinger, J. O.; Matyjaszewski, K. Rapid cellular internalization of multifunctional star polymers prepared by atom transfer radical polymerization. *Biomacromolecules* **2010**, *11*, 2199–203.
- (11) Duncan, R.; Ringsdorf, H.; Satchi-Fainaro, R. Polymer therapeutics: Polymers as drugs, drug and protein conjugates and gene delivery systems: Past, present and future opportunities. *Adv. Polym. Sci.* **2006**, *192*, 1–8.
- (12) Heath, W. H.; Senyurt, A. F.; Layman, J.; Long, T. E. Charged polymers via controlled radical polymerization and their implications for gene delivery. *Macromol. Chem. Phys.* **2007**, *208*, 1243–49.
- (13) Siegwart, D. J.; Whitehead, K. A.; Nuhn, L.; Sahay, G.; Cheng, H.; Jiang, S.; Ma, M. L.; Lytton-Jean, A.; Vegas, A.; Fenton, P.; Levins, C. G.; Love, K. T.; Lee, H.; Cortez, C.; Collins, S. P.; Li, Y. F.; Jang, J.; Querbes, W.; Zurenko, C.; Novobrantseva, T.; Langer, R.; Anderson, D. G. Combinatorial synthesis of chemically diverse core-shell nanoparticles for intracellular delivery. *Proc. Natl. Acad. Sci. U.S.A.* **2011**, *108*, 12996–3001.

- 268 (14) Li, S.; Rizzo, M. A.; Bhattacharya, S.; Huang, L. Characterization  
269 of cationic lipid-protamine-DNA (LPD) complexes for intravenous  
270 gene delivery. *Gene Ther.* **1998**, *5*, 930–37.
- 271 (15) Sokolova, V.; Epple, M. Inorganic nanoparticles as carriers of  
272 nucleic acids into cells. *Angew. Chem., Int. Ed.* **2008**, *47*, 1382–95.
- 273 (16) Liu, Y.; Huang, L. Designer Lipids Advance Systemic siRNA  
274 Delivery. *Mol. Ther.* **2010**, *18*, 669–70.
- 275 (17) Shim, M. S.; Kwon, Y. J. Controlled delivery of plasmid DNA  
276 and siRNA to intracellular targets using ketalized polyethylenimine.  
277 *Biomacromolecules* **2008**, *9*, 444–55.
- 278 (18) Lee, J. S.; Green, J. J.; Love, K. T.; Sunshine, J.; Langer, R.;  
279 Anderson, D. G. Gold, poly(beta-amino ester) nanoparticles for small  
280 interfering RNA delivery. *Nano Lett.* **2009**, *9*, 2402–06.
- 281 (19) Duzgunes, N.; De Ilarduya, C. T.; Simoes, S.; Zhdanov, R. I.;  
282 Konopka, K.; Pedroso de Lima, M. C. Cationic liposomes for gene  
283 delivery: Novel cationic lipids and enhancement by proteins and  
284 peptides. *Curr. Med. Chem.* **2003**, *10*, 1213–20.
- 285 (20) Xiong, F.; Mi, Z.; Gu, N. Cationic liposomes as gene delivery  
286 system: Transfection efficiency and new application. *Pharmazie* **2011**,  
287 *66*, 158–64.
- 288 (21) Tian, H.; Tang, Z.; Zhuang, X.; Chen, X.; Jing, X. Biodegradable  
289 synthetic polymers: Preparation, functionalization and biomedical  
290 application. *Prog. Polym. Sci.* **2012**, *37*, 237–80.
- 291 (22) Zhang, J.; Li, X.; Li, X. Stimuli-triggered structural engineering  
292 of synthetic and biological polymeric assemblies. *Prog. Polym. Sci.*  
293 **2012**, *37*, 1130–176.
- 294 (23) Boyer, C.; Priyanto, P.; Davis, T. P.; Pissuwan, D.; Bulmus, V.;  
295 Kavallaris, M.; Teoh, W. Y.; Amal, R.; Carroll, M.; Woodward, R.; St  
296 Pierre, T. Anti-fouling magnetic nanoparticles for siRNA delivery. *J.*  
297 *Mater. Chem.* **2010**, *20*, 255–65.
- 298 (24) McAllister, K.; Sazani, P.; Adam, M.; Cho, M. J.; Rubinstein, M.;  
299 Samulski, R. J.; DeSimone, J. M. Polymeric nanogels produced via  
300 inverse microemulsion polymerization as potential gene and antisense  
301 delivery agents. *J. Am. Chem. Soc.* **2002**, *124*, 15198–15207.
- 302 (25) Whitehead, K. A.; Langer, R.; Anderson, D. G. Knocking down  
303 barriers: Advances in siRNA delivery. *Nat. Rev. Drug Discovery* **2009**, *8*,  
304 129–38.
- 305 (26) Vaishnav, A. K.; Gollob, J.; Gamba-Vitalo, C.; Hutabarat, R.;  
306 Sah, D.; Meyers, R.; de Fougères, T.; Maraganore, J. A status report  
307 on RNAi therapeutics. *Silence* **2010**, *1*, 14.
- 308 (27) Xu, L.; Anchordoquy, T. Drug delivery trends in clinical trials  
309 and translational medicine: Challenges and opportunities in the  
310 delivery of nucleic acid-based therapeutics. *J. Pharm. Sci.* **2011**, *100*,  
311 38–52.
- 312 (28) O'Rourke, S.; Keeney, M.; Pandit, A. Non-viral polyplexes:  
313 Scaffold mediated delivery for gene therapy. *Prog. Polym. Sci.* **2010**, *35*,  
314 441–58.
- 315 (29) Oh, J. K.; Tang, C.; Gao, H.; Tsarevsky, N. V.; Matyjaszewski, K.  
316 Inverse miniemulsion ATRP: A new method for synthesis and  
317 functionalization of well-defined water-soluble/cross-linked polymeric  
318 particles. *J. Am. Chem. Soc.* **2006**, *128*, 5578–84.
- 319 (30) Oh, J. K.; Siegwart, D. J.; Lee, H.-i.; Sherwood, G.; Peteanu, L.;  
320 Hollinger, J. O.; Kataoka, K.; Matyjaszewski, K. Biodegradable  
321 nanogels prepared by atom transfer radical polymerization as potential  
322 drug delivery carriers: Synthesis, biodegradation, in vitro release, and  
323 bioconjugation. *J. Am. Chem. Soc.* **2007**, *129*, 5939–45.
- 324 (31) Oh, J. K.; Bencherif, S. A.; Matyjaszewski, K. Atom transfer  
325 radical polymerization in inverse miniemulsion: A versatile route  
326 toward preparation and functionalization of microgels/nanogels for  
327 targeted drug delivery applications. *Polymer* **2009**, *50*, 4407–23.
- 328 (32) Peeler, J. C.; Woodman, B. F.; Averick, S.; Miyake-Stoner, S. J.;  
329 Stokes, A. L.; Hess, K. R.; Matyjaszewski, K.; Mehl, R. A. Genetically  
330 encoded initiator for polymer growth from proteins. *J. Am. Chem. Soc.*  
331 **2010**, *132*, 13575–77.
- 332 (33) Averick, S. E.; Magenau, A. J. D.; Simakova, A.; Woodman, B.  
333 F.; Seong, A.; Mehl, R. A.; Matyjaszewski, K. Covalently incorporated  
334 protein-nanogels using AGET ATRP in an inverse miniemulsion.  
335 *Polym. Chem.* **2011**, *2*, 1476–78.
- (34) Oh, J. K.; Drumright, R.; Siegwart, D. J.; Matyjaszewski, K. The  
336 development of microgels/nanogels for drug delivery applications. *337*  
*Prog. Polym. Sci.* **2008**, *33*, 448–77. *338*
- (35) Oh, J. K.; Siegwart, D. J.; Matyjaszewski, K. Synthesis and  
339 biodegradation of nanogels as delivery carriers for carbohydrate drugs. *340*  
*Biomacromolecules* **2007**, *8*, 3326–31. *341*
- (36) Averick, S.; Simakova, A.; Park, S.; Konkolewicz, D.; Magenau,  
342 A. J. D.; Mehl, R. A.; Matyjaszewski, K. ATRP under biologically  
343 relevant conditions: Grafting from a protein. *ACS Macro Lett.* **2012**, *1*,  
344 6–10. *345*
- (37) Matyjaszewski, K.; Xia, J. H. Atom transfer radical polymer-  
346 ization. *Chem. Rev.* **2001**, *101*, 2921–90. *347*
- (38) Matyjaszewski, K. Atom transfer radical polymerization  
348 (ATRP): Current status and future perspectives. *Macromolecules*  
349 **2012**, *45*, 4015–39. *350*
- (39) Xu, F. J.; Yang, W. T. Polymer vectors via controlled/living  
351 radical polymerization for gene delivery. *Prog. Polym. Sci.* **2011**, *36*,  
352 1099–131. *353*
- (40) Averick, S.; Paredes, E.; Li, W. W.; Matyjaszewski, K.; Das, S. R.  
354 Direct DNA conjugation to star polymers for controlled reversible  
355 assemblies. *Bioconjugate Chem.* **2011**, *22*, 2030–37. *356*
- (41) Averick, S. E.; Paredes, E.; Grahacharya, D.; Woodman, B. F.;  
357 Miyake-Stoner, S. J.; Mehl, R. A.; Matyjaszewski, K.; Das, S. R.  
358 Protein-polymer, A hybrid mediated by DNA. *Langmuir* **2012**, *28*,  
359 1954–58. *360*
- (42) Nese, A.; Kwak, Y.; Nicolay, R.; Barrett, M.; Sheiko, S. S.;  
361 Matyjaszewski, K. Synthesis of poly(vinyl acetate) molecular brushes  
362 by a combination of atom transfer radical polymerization (ATRP) and  
363 reversible addition-fragmentation chain transfer (RAFT) polymer-  
364 ization. *Macromolecules* **2010**, *43*, 4016–19. *365*
- (43) Nese, A.; Lebedeva, N. V.; Sherwood, G.; Averick, S.; Li, Y. C.;  
366 Gao, H. F.; Peteanu, L.; Sheiko, S. S.; Matyjaszewski, K. pH-  
367 Responsive fluorescent molecular bottlebrushes prepared by atom  
368 transfer radical polymerization. *Macromolecules* **2011**, *44*, 5905–10. *369*
- (44) Siegwart, D. J.; Oh, J. K.; Matyjaszewski, K. ATRP in the design  
370 of functional materials for biomedical applications. *Prog. Polym. Sci.*  
371 **2012**, *37*, 18–37. *372*
- (45) Jaeger, W.; Bohrisch, J.; Laschewsky, A. Synthetic polymers with  
373 quaternary nitrogen atoms: Synthesis and structure of the most used  
374 type of cationic polyelectrolytes. *Prog. Polym. Sci.* **2010**, *35*, 511–77. *375*
- (46) Tsarevsky, N. V.; Matyjaszewski, K. Reversible redox cleavage/  
376 coupling of polystyrene with disulfide or thiol groups prepared by  
377 atom transfer radical polymerization. *Macromolecules* **2002**, *35*, 9009–  
378 14. *379*
- (47) Roy, D.; Cambre, J. N.; Sumerlin, B. S. Future perspectives and  
380 recent advances in stimuli-responsive materials. *Prog. Polym. Sci.* **2010**,  
381 *35*, 278–301. *382*
- (48) Oliveira, M. A. M.; Boyer, C.; Nele, M.; Pinto, J. C.; Zetterlund,  
383 P. B.; Davis, T. P. Synthesis of biodegradable hydrogel nanoparticles  
384 for bioapplications using inverse miniemulsion RAFT polymerization.  
385 *Macromolecules* **2011**, *44*, 7167–7175. *386*
- (49) Anderson, M. E. Glutathione: An overview of biosynthesis and  
387 modulation. *Chem. Biol. Interact.* **1998**, *111*, 1–14. *388*
- (50) Manickam, D. S.; Li, J.; Putt, D. A.; Zhou, Q. H.; Wu, C.; Lash,  
389 L. H.; Oupicky, D. Effect of innate glutathione levels on activity of  
390 redox-responsive gene delivery vectors. *J. Controlled Release* **2010**, *141*,  
391 77–84. *392*
- (51) Rogers, S. L.; Rogers, G. C. Culture of Drosophila S2 cells and  
393 their use for RNAi-mediated loss-of-function studies and immuno-  
394 fluorescence microscopy. *Nat. Protoc.* **2008**, *3*, 606–11. *395*
- (52) Arigita, C.; Zuidam, N. J.; Crommelin, D. J. A.; Hennink, W. E.  
396 Association and dissociation characteristics of polymer/DNA com-  
397 plexes used for gene delivery. *Pharm. Res.* **1999**, *16*, 1534–41. *398*
- (53) Ruby, J. G.; Jan, C. H.; Bartel, D. P. Intronic microRNA  
399 precursors that bypass Drosha processing. *Nature* **2007**, *448*, 83–6. *400*